LPA and coronary artery disorder: In the FOURIER study, in a group of patients with stable coronary artery disease treated with evolocumab, a reduction in serum Lp(a) concentration by 26.9% (6.2–46.7%) and a reduction of cardiovascular incidents by 23% (HR = 0.77; 95% Cl: 0.67–0.88) was achieved in subjects with baseline Lp(a) above the median (37 nmol/L; 15 mg/dL), while in the group with Lp(a) below the median only by 7% (HR = 0,93; 95% Cl: 0.80–1.08).